A shadow economy for unapproved weight-loss medications is being driven by social media fitness personalities and vendors on messaging platforms, based on new investigations.
Experimental Treatment Gaining Popularity Online
Retatrutide, which is still in clinical trials, is being promoted by online personalities for its supposed fat-burning properties. Viewers are urged to contact these accounts directly for supplier links, while also receiving discount codes.
Active Trade on Social Networks
Separately, a flourishing trade exists on messaging services, where groups with numerous of participants share comparison images, injection guides and assertions of next-day UK delivery. Sellers promote the drug there before directing buyers to WhatsApp for purchases.
Understanding Retatrutide
Retatrutide is an investigational injection developed by US drugmaker Eli Lilly. The drug targets three intestinal hormones – GLP-1, GIP and pancreatic hormone. Early trials indicate it could assist patients lose up to a quarter of their total weight. Referred to as the “triple G”, the drug is being hailed digitally as the successor to Ozempic.
Medical Professionals Voice Concerns
Nevertheless, doctors and pharmacists have warned that the sale of what remains an unapproved medication in the UK is worrisome and could result in individuals administering products of uncertain source.
Some experts stated the popularity for retatrutide could be linked to the rising price of licensed weight loss treatments such as Mounjaro.
Regulatory Position and Enforcement
Marketing the unapproved drug on social media or Telegram is illegal in the UK, as it is an unapproved drug that must not be marketed or distributed for personal consumption under the Human Medicines Regulations 2012.
Several influencers attempt to circumvent the regulations by calling to the drug as a “research chemical” or describing it as “not for human consumption”. The substance is not a restricted drug, but advertising and distribution can still violate medicines, advertising, and customer laws, potentially leading to fines, prosecution or prison.
Service Response and Content Elimination
According to the social media company, the platform has removed problematic content and prohibited associated hashtags and query recommendations. The organization stated it was dedicated to maintaining the platform safe and allocating resources in enhancing enforcement strategies.
Online Marketplace Activities
Research also found groups with up to 9,000 participants marketing the experimental drug using Telegram's built-in search feature, which functions like a public directory. Entering “retatrutide” instantly brings up channels with thousands of members, populated with images of weight loss, positive reviews and detailed instructions for preparing or administering at home.
After moments of entering one community, a seller posted WhatsApp details, where the majority of transactions occur. The vendor provided an guidebook and guaranteed delivery within 48 hours. When asked whether the substance was genuine, one vendor said: “You can’t be sure.” Another provided a photo of a alleged laboratory certificate. None asked about weight, health issues or past usage.
Product Information and Costs
Within these groups, posts display black plastic parcels with Royal Mail stickers, claiming to contain new batches. One message stated: “It took eight of us to load them this morning.”
Customers can choose between powder vials, prepared at home with sterile water, or ready-to-use pens typically priced at £160 for 20mg. When questioned how much time a injector should be used, sellers give contradictory responses ranging from a several days to “depends on your body”.
Platform Oversight and Safety Actions
A representative for the messaging service said it regularly monitored dangerous content on its platform including content that promoted the “misuse of controlled medications”. The organization added that it eliminated “millions of pieces of harmful content each day”.
Medical Expert Cautions
“People are administering substances they cannot confirm. Although the research behind this drug is sound, these online products may not include what they claim,” said Jason Murphy, the director of pharmaceutical services at Chemist4U.
Dr Crystal Wyllie of an online medical service linked the surge in interest to recent price rises for authorized weight-loss drugs such as Mounjaro. “With costs rising, individuals are using social media. But counterfeit injections are extremely dangerous. You cannot know what’s inside or whether the environment they were produced in was clean,” she said.
Her staff has previously seen patients harmed by self-injection from unverified suppliers. “We understand the frustration, but purchasing from Telegram or communication platforms is gambling with your well-being,” said the doctor. “These substances could be impure or improperly measured.”
Manufacturer Statement
A spokesperson from Eli Lilly stated the substance was in phase 3 clinical trials and had not been reviewed or approved by any regulatory agency globally. “Consequently at this time no one can market [it] for human use,” they said, adding that any product “misleadingly claiming itself as a company investigational substance not yet approved … may subject users to possibly serious medical dangers”.
